Can PLI, China Plus One keep India’s pharma sector in pink of health?

Can PLI, China Plus One keep India’s pharma sector in pink of health?

The US economy also witnessed substantial issues in its pharma market. In addition to these, manufacturing & exporting countries around the world saw heightened raw material price inflation followed by supply chain disruption. All these affected the margins of the companies deeply. Synopsis Indian pharmaceutical market flattened after the pandemic led to a massive upsurge … Read more

Over 158 applications for generic products pending with USFDA for approval: Lupin

Over 158 applications for generic products pending with USFDA for approval: Lupin

NEW DELHI:Drug firm Lupin remains bullish over its US business with over 158 applications for generic products pending with the US drug regulator for approval, as per the company’s annual report for 2019-20. Sharing information with company’s shareholders, Lupin MD Nilesh Gupta and CEO Vinita Gupta said the company’s US business stabilised last fiscal and … Read more